US Patent

US10300065 — Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction

Method of Use · Assigned to AstraZeneca AB · Expires 2036-01-27 · 10y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of administering 60 mg ticagrelor twice daily to patients with a history of myocardial infarction to reduce cardiovascular death, myocardial infarction, or stroke.

USPTO Abstract

The present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient a pharmaceutical composition comprising 60 mg ticagrelor twice daily.

Drugs covered by this patent

Brilinta (ticagrelor) · AstraZeneca

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2541`	—	Brilinta
`U-2541`	—	Brilinta

Patent Metadata

Patent number: US10300065
Jurisdiction: US
Classification: Method of Use
Expires: 2036-01-27
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.